Takeda and colleagues (2010) generated a double transgenic APP+/ob model to undertake their investigation and found that within 8 weeks, these mice displayed marked phenotypes of hyperglycaemia, hyperinsulinemia, and glucose intolerance as compared to the APP+ cohort [412]. The gene discussed is APP; the disease is hyperinsulinism.